NLRP3 inflammasome: the core mechanism and potential target of inflammatory response in Alzheimer's disease

doi:10.3969/j.issn.1672-6731.2020.01.006

Abstract

Abstract:

Alzheimer's disease (AD) is the most common cause of cognitive impairment in the elderly. However, the pathogenesis of AD remains unclear. Persistent excessive inflammatory response plays a pivotal role in the development of AD. It has been suggested that activation of the nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome is important for inflammatory response in AD. This article reviews the structure and activation of NLRP3 inflammasome and the specific inhibitors of NLRP3 inflammasome.

Key words: Alzheimer disease, Inflammation, NLRP3 inflammasome (not in MeSH), Review

摘要：

阿尔茨海默病是导致老年人认知功能障碍最为常见的疾病，其具体发病机制迄今尚未阐明，持续过度的炎症反应在阿尔茨海默病的病理生理学机制中发挥重要作用。核苷酸结合寡聚化结构域样受体蛋白3（NLRP3）炎症小体信号转导通路是阿尔茨海默病炎症反应的关键环节，本文拟对NLRP3炎症小体的结构和激活机制、参与阿尔茨海默病炎症反应的机制以及特异性NLRP3炎症小体抑制剂进行综述。

关键词: 阿尔茨海默病, 炎症, NLRP3炎症小体（非MeSH词）, 综述

SHI Jian-quan, XU Jun. NLRP3 inflammasome: the core mechanism and potential target of inflammatory response in Alzheimer's disease[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(1): 29-33.

时建铨, 徐俊. NLRP3炎症小体：阿尔茨海默病炎症反应核心机制及潜在靶点[J]. 中国现代神经疾病杂志, 2020, 20(1): 29-33.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2020.01.006

https://journal11.magtechjournal.com/cjcnn/EN/Y2020/V20/I1/29

References

[1] GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015:a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Neurol, 2017, 16:877-897.
[2] Lane CA, Hardy J, Schott JM. Alzheimer's disease[J]. Eur J Neurol, 2018, 25:59-70.
[3] Hammond TR, Marsh SE, Stevens B. Immune signaling in neurodegeneration[J]. Immunity, 2019, 50:955-974.
[4] Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors[J]. Cell Death Dis, 2019, 10:128.
[5] Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition:a cell biological perspective[J]. Annu Rev Immunol, 2015, 33:257-290.
[6] Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease[J]. Nat Rev Neurosci, 2018, 19:610-621.
[7] Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome:molecular activation and regulation to therapeutics[J]. Nat Rev Immunol, 2019.[Epub ahead of print]
[8] Guo H, Callaway JB, Ting JP. Inflammasomes:mechanism of action, role in disease, and therapeutics[J]. Nat Med, 2015, 21:677-687.
[9] Gao L, Dong Q, Song Z, Shen F, Shi J, Li Y. NLRP3 inflammasome:a promising target in ischemic stroke[J]. Inflamm Res, 2017, 66:17-24.
[10] Shi J, Gao W, Shao F. Pyroptosis:gasdermin-mediated programmed necrotic cell death[J]. Trends Biochem Sci, 2017, 42:245-254.
[11] Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease[J]. J Cell Biol, 2018, 217:459-472.
[12] Gustin A, Kirchmeyer M, Koncina E, Felten P, Losciuto S, Heurtaux T, Tardivel A, Heuschling P, Dostert C. NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes[J]. PLoS One, 2015, 10:E0130624.
[13] Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppinen A. Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer's pathology[J]. J Cell Mol Med, 2008, 12:2255-2262.
[14] Lue LF, Rydel R, Brigham EF, Yang LB, Hampel H, Murphy GM Jr, Brachova L, Yan SD, Walker DG, Shen Y, Rogers J. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro[J]. Glia, 2001, 35:72-79.
[15] Zuliani G, Ranzini M, Guerra G, Rossi L, Munari MR, Zurlo A, Volpato S, Atti AR, Blè A, Fellin R. Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia[J]. J Psychiatr Res, 2007, 41:686-693.
[16] Ojala J, Alafuzoff I, Herukka SK, van Groen T, Tanila H, Pirttilä T. Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients[J]. Neurobiol Aging, 2009, 30:198-209.
[17] Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients[J]. Neurosci Lett, 1995, 202(1/2):17-20.
[18] Apelt J, Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology[J]. Brain Res, 2001, 894:21-30.
[19] Pompl PN, Yemul S, Xiang Z, Ho L, Haroutunian V, Purohit D, Mohs R, Pasinetti GM. Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease[J]. Arch Neurol, 2003, 60:369-376.
[20] Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL 3rd, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease[J]. Proc Natl Acad Sci USA, 1989, 86:7611-7615.
[21] Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease[J]. Neuron, 2006, 49:489-502.
[22] Griffin WS, Liu L, Li Y, Mrak RE, Barger SW. Interleukin-1 mediates Alzheimer and Lewy body pathologies[J]. J Neuroinflammation, 2006, 3:5.
[23] Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology[J]. J Clin Invest, 2007, 117:1595-1604.
[24] Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta[J]. Nat Immunol, 2008, 9:857-865.
[25] Wang BR, Shi JQ, Ge NN, Ou Z, Tian YY, Jiang T, Zhou JS, Xu J, Zhang YD. PM2.5 exposure aggravates oligomeric amyloid beta-induced neuronal injury and promotes NLRP3 inflammasome activation in an in vitro model of Alzheimer's disease[J]. J Neuroinflammation, 2018, 15:132.
[26] Shi JQ, Zhang CC, Sun XL, Cheng XX, Wang JB, Zhang YD, Xu J, Zou HQ. Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-κ B and NLRP3 inflammasome activation[J]. CNS Neurosci Ther, 2013, 19:262-268.
[27] Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice[J]. Nature, 2013, 493:674-678.
[28] Tan MS, Tan L, Jiang T, Zhu XC, Wang HF, Jia CD, Yu JT. Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer's disease[J]. Cell Death Dis, 2014, 5:E1382.
[29] Dempsey C, Rubio Araiz A, Bryson KJ, Finucane O, Larkin C, Mills EL, Robertsom AA, Cooper MA, O'Neill LA, Lynch MA. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice[J]. Brain Behav Immun, 2017, 61:306-316.
[30] Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease[J]. Nat Med, 2015, 21:263-269.
[31] Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, Meng R, Quong AA, Latz E, Scott CP, Alnemri ES. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome[J]. J Biol Chem, 2010, 285:9792-9802.
[32] Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA. Age and age-related diseases:role of inflammation triggers and cytokines[J]. Front Immunol, 2018, 9:586.
[33] Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, Croker DE, Butler MS, Haneklaus M, Sutton CE, Núñez G, Latz E, Kastner DL, Mills KH, Masters SL, Schroder K, Cooper MA, O'Neill LA. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases[J]. Nat Med, 2015, 21:248-255.
[34] Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, Wang A, Tao J, Wang C, Liu Q, Jin T, Jiang W, Deng X, Zhou R. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders[J]. J Exp Med, 2017, 214:3219-3238.
[35] Marchetti C, Swartzwelter B, Koenders MI, Azam T, Tengesdal IW, Powers N, de Graaf DM, Dinarello CA, Joosten LA. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis[J]. Arthritis Res Ther, 2018, 20:169.
[36] Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, Carta S, Tengesdal I, Nemkov T, D'Alessandro A, Henry C, Jones GS, Goodrich SA, St Laurent JP, Jones TM, Scribner CL, Barrow RB, Altman RD, Skouras DB, Gattorno M, Grau V, Janciauskiene S, Rubartelli A, Joosten LA, Dinarello CA. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation[J]. Proc Natl Acad Sci USA, 2018, 115:E1530-1539.
[37] Darakhshan S, Pour AB. Tranilast:a review of its therapeutic applications[J]. Pharmacol Res, 2015, 91:15-28.
[38] Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, Deng X, Liang G, Zhang H, Jiang W, Zhou R. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases[J]. EMBO Mol Med, 2018, 10:piiE8689.
[39] Kuo LM, Kuo CY, Lin CY, Hung MF, Shen JJ, Hwang TL. Intracelluar glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells[J]. Molecules, 2014, 19:3327-3344.
[40] Kadota S, Basnet P, Ishii E, Tamura T, Namba T. Antibacterial activity of trichorabdal A from Rabdosia trichocarpa against Helicobacter pylori[J]. Zentralbl Bakteriol, 1997, 286:63-67.
[41] Yang J, Jiang H, Wang C, Yang B, Zhao L, Hu D, Qiu G, Dong X, Xiao B. Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects[J]. Biomed Pharmacother, 2015, 72:125-134.
[42] He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, Liu Q, Liang G, Deng X, Jiang W, Zhou R. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity[J]. Nat Commun, 2018, 9:2550.
[43] Li Q, Chen L, Liu X, Li X, Cao Y, Bai Y, Qi F. Pterostilbene inhibits amyloid-β-induced neuroinflammation in a microglia cell line by inactivating the NLRP3/Caspase-1 inflammasome pathway[J]. J Cell Biochem, 2018, 119:7053-7062.
[44] Wang CY, Xu Y, Wang X, Guo C, Wang T, Wang ZY. Dl-3-N-butylphthalide inhibits NLRP3 inflammasome and mitigates Alzheimer's-like pathology via Nrf2-TXNIP-TrX axis[J]. Antioxid Redox Signal, 2019, 30:1411-1431.
[45] Stancu IC, Cremers N, Vanrusselt H, Couturier J, Vanoosthuyse A, Kessels S, Lodder C, Brône B, Huaux F, Octave JN, Terwel D, Dewachter I. Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo[J]. Acta Neuropathol, 2019, 137:599-617.

Please choose a citation manager

Content to export